On 6 August 2024, Amgen announced its financial results for Q2/2024, reporting total revenues increased 20% to US$8.4 billion compared with Q2/2023. Twelve of its products delivered at least double-digit sales growth in the quarter, including Prolia® (denosumab), Repatha® (evolocumab), Evenity® (romosozumab-aqqg), Tezspire® (tezepelumab-ekko) and Blincyto® (blinatumomab).
Biosimilar highlights for the quarter include the FDA approval of Amgen’s Bkemv® as the first interchangeable biosimilar to Alexion’s Soliris® (eculizumab) in May 2024, initiation of a Ph 3 study in May 2024 to compare efficacy and safety of Amgen’s ABP 234 with Keytruda® (pembrolizumab), and the enrolment of patients in a study evaluating pharmacokinetic similarity of Amgen’s ABP 206 compared with BMS’ Opdivo® (nivolumab).